96 results on '"Townson S"'
Search Results
2. P164 MRT-6160, a VAV1-directed molecular glue degrader, inhibits disease progression and inflammation in a T-cell transfer model of Colitis
- Author
-
Cartwright Ph.D, A, primary, Desai, F, additional, Nguyen, S, additional, Trouilloud, A, additional, Vora, S, additional, Gyger, L, additional, Roditi, L, additional, Lam, D, additional, Trenh, P, additional, Lucas, X, additional, Zlotosch, M, additional, Liardo, E, additional, Wible, D, additional, Oleinikovas, V, additional, Lamberto, I, additional, Demarco, B, additional, King, C, additional, Bonenfant, D, additional, Townson, S, additional, Wallace, O, additional, Krishnan, E, additional, De Beukelaer, S, additional, Janku, F, additional, McAllister, L, additional, Paterson, A, additional, and Peluso, M, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Antiparasitic properties of medicinal plants and other naturally occurring products
- Author
-
TAGBOTO, S, primary and TOWNSON, S, additional
- Published
- 2001
- Full Text
- View/download PDF
4. Artificial feeding and successful reproduction inOrnithodoros moubata moubata (Murray, 1877) (Acarina: Argasidae)
- Author
-
Schwan, E. V., Hutton, D., Shields, K. J. B., and Townson, S.
- Published
- 1991
- Full Text
- View/download PDF
5. Synthesis of novel N-substituted 3-(aminosulfonyl)-2H-1-benzopyran-2-one derivatives and their biological activity
- Author
-
Kovalenko, S.S., Silin, O.V., Kovalenko, S.M., Chernykh, V.P., Maes, Louis, Townson, S., Yousif, F., Fakorede, F., Bernadette, R., and Nwaka, S.
- Subjects
Chemistry ,Pharmacology. Therapy - Published
- 2009
6. Synthesis of novel N-substituted 3-(aminosulfonyl)-2h-l-benzopyran-2-one derivatives and their biological activity
- Author
-
Kovalenko, S.S., Silin, O.V., Kovalenko, S.M., Chernykh, V.P., Maes, L., Townson, S., Yousif, F., Fakorede, F., Bernadette, R., and Nwaka, S.
- Abstract
New N-substituted 3-(aminosulfonyl)-2H-1 -benzopyran-2-one derivatives were synthesized by the reaction of salicylic aldehydes with N-substituted ethyl 2-(aminosulfonyl)acetates in the Knoevenagel condensation conditions. The structure of obtained compounds was determined through a complete IR- and ¹H NMR analysis. The biological activity of some derivatives against protozoan and helminth parasites was studied. Some compounds were active against Onchocerca lienalis. Нові N-заміщені похідні 3-(аміносульфоніл)-2Н-1 -бензопіран-2-онів були синтезовані за реакцією саліцилових альдегідів з N-заміщеними етил 2-(аміносульфоніл)ацетатами в умовах конденсації за Кньовенагелем. Структуру отриманих сполук було визначено методами ІЧ- та ПМР-спектроскопії. Вивчено біологічну активність отриманих сполук проти протозойних та гельмінтних паразитів. Деякі сполуки виявили високу активність проти Onchocerca lienalis. Новые N-замещенные производные 3-(аминосульфонил)-2Н-1-бензопиран-2-онов были синтезованы реакцией салициловых альдегидов с N-замещенными этил 2-(аминосульфо-нил)ацетатами в условиях конденсации Кневенагеля. Структура полученных соединений была подтверждена методами ИК- и ПМР-спектроскопии. Изучена биологическая активность полученных соединений против протозойных и гельминтных паразитов. Некоторые соединения проявили высокую активность по отношению к Onchocerca lienalis.
- Published
- 2009
7. Estrogen receptor corepressors -- a role in human breast cancer?
- Author
-
Dobrzycka, K M, primary, Townson, S M, additional, Jiang, S, additional, and Oesterreich, S, additional
- Published
- 2003
- Full Text
- View/download PDF
8. Potential transition state phosphoramidate inhibitors of β-tubulin as antifilarial agents
- Author
-
Anderson, R J, primary, Bendell, D J, additional, Hooper, M, additional, Cairns, D, additional, Mackay, S P, additional, Hiremath, S P, additional, Jivanagi, A S, additional, Badami, S, additional, Biradar, J S, additional, and Townson, S, additional
- Published
- 2001
- Full Text
- View/download PDF
9. Antibiotics andWolbachiain filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol againstOnchocerca gutturosa,Onchocerca lienalisandBrugia pahangi
- Author
-
Townson, S., primary, Hutton, D., additional, Siemienska, J., additional, Hollick, L., additional, Scanlon, T., additional, Tagboto, S. K., additional, and Taylor, M. J., additional
- Published
- 2000
- Full Text
- View/download PDF
10. Immune responses of the argasid tick Ornithodoros moubata moubata induced by infection with the filarial worm Acanthocheilonema viteae
- Author
-
Hutton, D., primary, Reid, A.P., additional, and Townson, S., additional
- Published
- 2000
- Full Text
- View/download PDF
11. Cloning and characterization of a novel human gene related to vascular endothelial growth factor.
- Author
-
Grimmond, S, primary, Lagercrantz, J, additional, Drinkwater, C, additional, Silins, G, additional, Townson, S, additional, Pollock, P, additional, Gotley, D, additional, Carson, E, additional, Rakar, S, additional, Nordenskjöld, M, additional, Ward, L, additional, Hayward, N, additional, and Weber, G, additional
- Published
- 1996
- Full Text
- View/download PDF
12. Onchocerca volvulusandO. lienalis:the microfilaricidal activity of moxidectin compared with that of ivermectinin vitroandin vivo
- Author
-
Tagboto, S. K., primary and Townson, S., additional
- Published
- 1996
- Full Text
- View/download PDF
13. Acanthocheilonema viteae: Reduction in the Expression of Protective Immunity against Infective Larvae in the Jird as Assessed by Micropore Chamber vs Systemic Challenge Infections
- Author
-
Taylor, M.J., primary, Vanes, R.P., additional, Shay, K., additional, Townson, S., additional, and Bianco, A.E., additional
- Published
- 1995
- Full Text
- View/download PDF
14. Comparison of the sensitivity of different geographical isolates of Onchocerca volvulus microfilariae to ivermectin: effects of exposure to drug on development in the blackfly Simulium ornatum
- Author
-
Tagboto, S.K., primary, Townson, S., additional, Titanji, V.P.K., additional, Awadzi, K., additional, Castro, J., additional, and Zea-Flores, G., additional
- Published
- 1994
- Full Text
- View/download PDF
15. Comparison of the sensitivity of different geographical races of Onchocerca volvulus microfilariae to ivermectin: studies in vitro
- Author
-
Townson, S., primary, Tagboto, S.K., additional, Castro, J., additional, Lujan, A., additional, Awadzi, K., additional, and Titanji, V.P.K., additional
- Published
- 1994
- Full Text
- View/download PDF
16. Host strain, H-2 genotype and immunocompetence do not affect the survival or development of Onchocerca lienalis infective larvae implanted within micropore chambers into mice or rats
- Author
-
Taylor, M. J., primary, Van Es, R. P., additional, Townson, S., additional, and Bianco, A. E., additional
- Published
- 1992
- Full Text
- View/download PDF
17. Onchocerca lienalis:comparison of techniques for the cryopreservation of microfilariae within skin-snips or free of host tissues
- Author
-
Tagboto, S. K., primary and Townson, S., additional
- Published
- 1991
- Full Text
- View/download PDF
18. Characterisation and purification of pyruvate:ferredoxin oxidoreductase from Giardia duodenalis
- Author
-
Townson, S. M., Upcroft, J. A., and Upcroft, P.
- Published
- 1996
- Full Text
- View/download PDF
19. Experimental infection of mice with the microfilariae of Onchocerca lienalis.
- Author
-
Townson, S. and Bianco, A. E.
- Published
- 1982
- Full Text
- View/download PDF
20. An improved technique for the cryopreservation of Onchocerca microfilariae.
- Author
-
Ham, P. J., Townson, S., James, E. R., and Bianco, A. E.
- Published
- 1981
- Full Text
- View/download PDF
21. Attempts to infect small laboratory animals with the infective larvae of Onchocerca lienalis
- Author
-
Townson, S., primary, Bianco, A. E., additional, and Owen, Dawn, additional
- Published
- 1981
- Full Text
- View/download PDF
22. Experimental infection of mice with the microfilariae ofOnchocerca lienalis
- Author
-
Townson, S., primary and Bianco, A. E., additional
- Published
- 1982
- Full Text
- View/download PDF
23. Acanthocheilonema viteae:Reduction in the Expression of Protective Immunity against Infective Larvae in the Jird as Assessed by Micropore Chamber vs Systemic Challenge Infections
- Author
-
Taylor, M.J., Vanes, R.P., Shay, K., Townson, S., and Bianco, A.E.
- Published
- 1995
- Full Text
- View/download PDF
24. Antibiotics and Wolbachiain filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa , Onchocerca lienalisand Brugia pahangi.
- Author
-
Townson, S., Hutton, D., Siemienska, J., Hollick, L., Scanlon, T., Tagboto, S. K., and Taylor, M. J.
- Subjects
- *
EFFECT of antibiotics on microorganisms , *TREATMENT of filariasis - Abstract
The activity against filarial parasites of the antibiotics rifampicin, oxytetracycline and chloramphenicol was examined. In addition, transmission electron microscopy was used to study the effects of rifampicin and oxytetracycline on filarial tissues and on the endosymbiont bacterium, Wolbachia . When tested in vitro at a concentration of 50.0 μM, each of the three antibiotics significantly reduced the motility levels of male Onchocerca gutturosa . Rifampicin, however, was the most active, virtually immobilizing the parasite by the end of the 40-day trial and producing an 84% reduction in viability (as measured by formazan-based colorimetry). In tests against O. lienalis microfilariae (mff) in CBA mice, the numbers of mff recovered after treatment with oxytetracycline at 100, 25 or 6.5 mg/kg daily, for 15 days, were 56% ( P ≤ 0.03), 38% ( P > 0.05) and 45% ( P = 0.05) less than that recovered from the untreated controls, respectively. In another trial in mice, rifampicin (100 mg/kg daily for 15 days) was found to be the most active (causing a 74% reduction in the number of mff recovered—approximately equal to that achieved with the positive control of a single dose of ivermectin at 2 μg/kg), with chloramphenicol also showing significant activity (39% reduction). In further, in-vivo trials, at three dose levels (100, 25 or 6.25 mg/kg daily, for 15 days), all three antibiotics were tested against adult Brugia pahangi in the peritoneal cavities of jirds. None of the antibiotics produced a significant reduction in the numbers of live worms recovered, although a marginal effect was observed in eight of the nine antibiotic-treated groups. A further extended trial with rifampicin and oxytetracycline resulted in 43% and 38% reductions in worm recoveries, respectively (not statistically significant but consistent with a marginal effect); some of these worms appeared less motile and qualitativ... [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
25. Artificial feeding and successful reproduction in Ornithodoros moubata moubata (Murray, 1877) (Acarina: Argasidae)
- Author
-
Hutton, D., Townson, S., Schwan, E. V., and Shields, K. J. B.
- Subjects
ARTIFICIAL feeding - Published
- 1991
26. Resistance to nitroheterocyclic drugs
- Author
-
Townson, S. M., Boreham, P. F. L., Upcroft, P., and Upcroft, J. A.
- Published
- 1994
- Full Text
- View/download PDF
27. Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia.
- Author
-
Gokool S, Townson S, Freeman A, Siemienski-Kleyn J, Zubrzycki J, Tagboto S, Hübner MP, and Scandale I
- Abstract
Onchocerciasis treatment and control relies mainly on the use of ivermectin which has high activity against the microfilarial stage of Onchocerca volvulus but limited activity against the long-lived, tissue dwelling adult nematodes. As this neglected tropical disease has now been targeted for elimination, there is an urgent need for new drugs to combat these parasites, ideally with macrofilaricidal activity. In this study, we have examined the anti- Onchocerca activity of a range of existing FDA-approved drugs with a view to repurposing, which can lead to rapid and relatively inexpensive development. From the Pharmakon-1600 library, 106 drugs were selected and tested against O. gutturosa adult male parasites using a concentration of 1.25 × 10
-5 M in an in vitro 5-day standard assay to assess motility and viability (using MTT/formazan colorimetry). The findings revealed that 44 drugs produced marginal/moderate activity (50-99% motility and/or MTT reductions) including cefuroxime sodium, methenamine, primaquine phosphate and rivastigmine tartrate, while 23 drugs produced good activity (100% motility reductions and significant MTT reductions), including atovaquone, isradipine, losartan, rifaximin, cefaclor and pyrantel pamoate. Although this study represents only a first step, some of the identified hits indicate there are potential anti- Onchocerca drug candidates worthy of further investigation.- Published
- 2024
- Full Text
- View/download PDF
28. Discovery of Substituted Di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as Novel Macrofilaricidal Compounds for the Treatment of Human Filarial Infections.
- Author
-
Hawryluk N, Robinson D, Shen Y, Kyne G, Bedore M, Menon S, Canan S, von Geldern T, Townson S, Gokool S, Ehrens A, Koschel M, Lhermitte-Vallarino N, Martin C, Hoerauf A, Hernandez G, Dalvie D, Specht S, Hübner MP, and Scandale I
- Subjects
- Adult, Amines, Humans, Elephantiasis, Filarial, Onchocerciasis
- Abstract
Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered among the most devastating of all tropical diseases, affecting about 145 million people worldwide. Efforts to control and eliminate onchocerciasis are impeded by a lack of effective treatments that target the adult filarial stage. Herein, we describe the discovery of a series of substituted di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as novel macrofilaricides for the treatment of human filarial infections.
- Published
- 2022
- Full Text
- View/download PDF
29. Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization.
- Author
-
Hawryluk N, Zhiru L, Carlow C, Gokool S, Townson S, Kreiss T, Chojnowski A, Prorok M, Siekierka J, Ehrens A, Koschel M, Lhermitte-Vallarino N, Martin C, Hoerauf A, Hernandez G, Canan S, Khetani V, Zeldis J, Specht S, Hübner MP, and Scandale I
- Subjects
- Adult, Animals, Caenorhabditis elegans, Cats, Cattle, Drug Discovery, Humans, Mice, Onchocerca, Rats, Brugia malayi, Onchocerciasis parasitology, Parasites
- Abstract
Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered among the most devastating of all tropical diseases, affecting over 86 million people worldwide. To control and more rapidly eliminate onchocerciasis requires treatments that target the adult stage of the parasite. Drug discovery efforts are challenged by the lack of preclinical animal models using the human-pathogenic filariae, requiring the use of surrogate parasites for Onchocerca volvulus for both ex vivo and in vivo evaluation. Herein, we describe a platform utilizing phenotypic ex vivo assays consisting of the free-living nematode Caenorhabditis elegans, microfilariae and adult filariae of the bovine filariae Onchocerca lienalis and Onchocerca gutturosa, respectively, as well as microfilariae and adult filariae of the feline filariae Brugia pahangi, the rodent filariae Litomosoides sigmodontis and the human-pathogenic filariae Brugia malayi to assess activity across various surrogate parasites. Utilization of those surrogate nematodes for phenotypic ex vivo assays in order to assess activity across various parasites led to the successful establishment of a screening cascade and identification of multiple compounds with potential macrofilaricidal activity and desirable physicochemical, MW = 200-400 and low lipophilicity, logP <4, and pharmacokinetic properties, rat and human liver S9 stability of ≥70% remaining at 60 min, and AUC exposures above 3 μM h. This platform demonstrated the successful establishment of a screening cascade which resulted in the discovery of potential novel macrofilaricidal compounds for futher drug discovery lead optimization efforts. This screening cascade identified two distinct chemical series wherein one compound produced a significant 68% reduction of adult Litomosoides sigmodontis in the mouse model. Successful demonstration of efficacy prompted lead optimization medicinal chemistry efforts for this novel series., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
30. Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside.
- Author
-
Hübner MP, Townson S, Gokool S, Tagboto S, Maclean MJ, Verocai GG, Wolstenholme AJ, Frohberger SJ, Hoerauf A, Specht S, Scandale I, Harder A, Glenschek-Sieberth M, Hahnel SR, and Kulke D
- Subjects
- Animals, Cats, Dogs, Brugia malayi, Depsipeptides, Elephantiasis, Filarial, Loiasis
- Abstract
Filariae are vector-borne nematodes responsible for an enormous burden of disease. Human lymphatic filariasis, caused by Wuchereria bancrofti, Brugia malayi, and Brugia timori, and onchocerciasis (caused by Onchocerca volvulus) are neglected parasitic diseases of major public health significance in tropical regions. To date, therapeutic efforts to eliminate human filariasis have been hampered by the lack of a drug with sufficient macrofilaricidal and/or long-term sterilizing effects that is suitable for use in mass drug administration (MDA) programs, particularly in areas co-endemic with Loa loa, the causative agent of loiasis. Emodepside, a semi-synthetic cyclooctadepsipeptide, has been shown to have broad-spectrum efficacy against gastrointestinal nematodes in a variety of mammalian hosts, and has been approved as an active ingredient in dewormers for cats and dogs. This paper evaluates, compares (where appropriate) and summarizes the in vitro effects of emodepside against a range of filarial nematodes at various developmental stages. Emodepside inhibited the motility of all tested stages of filariae frequently used as surrogate species for preclinical investigations (Acanthocheilonema viteae, Brugia pahangi, Litomosoides sigmodontis, Onchocerca gutturosa, and Onchocerca lienalis), human-pathogenic filariae (B. malayi) and filariae of veterinary importance (Dirofilaria immitis) in a concentration-dependent manner. While motility of all filariae was inhibited, both stage- and species-specific differences were observed. However, whether these differences were detected because of stage- and/or species-specific factors or as a consequence of variations in protocol parameters among the participating laboratories (such as purification of the parasites, read-out units, composition of media, incubation conditions, duration of incubation etc.) remains unclear. This study, however, clearly shows that emodepside demonstrates broad-spectrum in vitro activity against filarial nematode species across different genera and can therefore be validated as a promising candidate for the treatment of human filariases, including onchocerciasis and lymphatic filariasis., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. Development of emodepside as a possible adulticidal treatment for human onchocerciasis-The fruit of a successful industrial-academic collaboration.
- Author
-
Krücken J, Holden-Dye L, Keiser J, Prichard RK, Townson S, Makepeace BL, Hübner MP, Hahnel SR, Scandale I, Harder A, and Kulke D
- Subjects
- Humans, Antiparasitic Agents therapeutic use, Depsipeptides therapeutic use, Drug Development methods, Onchocerciasis drug therapy
- Abstract
Current mass drug administration (MDA) programs for the treatment of human river blindness (onchocerciasis) caused by the filarial worm Onchocerca volvulus rely on ivermectin, an anthelmintic originally developed for animal health. These treatments are primarily directed against migrating microfilariae and also suppress fecundity for several months, but fail to eliminate adult O. volvulus. Therefore, elimination programs need time frames of decades, well exceeding the life span of adult worms. The situation is worsened by decreased ivermectin efficacy after long-term therapy. To improve treatment options against onchocerciasis, a drug development candidate should ideally kill or irreversibly sterilize adult worms. Emodepside is a broad-spectrum anthelmintic used for the treatment of parasitic nematodes in cats and dogs (Profender and Procox). Our current knowledge of the pharmacology of emodepside is the result of more than 2 decades of intensive collaborative research between academia and the pharmaceutical industry. Emodepside has a novel mode of action with a broad spectrum of activity, including against extraintestinal nematode stages such as migrating larvae or macrofilariae. Therefore, emodepside is considered to be among the most promising candidates for evaluation as an adulticide treatment against onchocerciasis. Consequently, in 2014, Bayer and the Drugs for Neglected Diseases initiative (DNDi) started a collaboration to develop emodepside for the treatment of patients suffering from the disease. Macrofilaricidal activity has been demonstrated in various models, including Onchocerca ochengi in cattle, the parasite most closely related to O. volvulus. Emodepside has now successfully passed Phase I clinical trials, and a Phase II study is planned. This Bayer-DNDi partnership is an outstanding example of "One World Health," in which experience gained in veterinary science and drug development is translated to human health and leads to improved tools to combat neglected tropical diseases (NTDs) and shorten development pathways and timelines in an otherwise neglected area., Competing Interests: I have read the journal’s policy and want to declare the following conflicts of interest. The authors DK, SH, AH were employees of Bayer Animal Health GmbH, Germany. Bayer Animal Health GmbH was a company that developed and commercialized veterinary medicines including anthelmintics. The remaining authors of this manuscript have declared no competing interests.
- Published
- 2021
- Full Text
- View/download PDF
32. Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma.
- Author
-
Scherrer E, Rau R, Lorenzi M, Shui I, Townson S, and Larkin J
- Subjects
- Biomarkers, Tumor genetics, Clinical Decision-Making methods, Humans, Melanoma genetics, Melanoma immunology, Melanoma mortality, Patient Selection, Programmed Cell Death 1 Receptor antagonists & inhibitors, Progression-Free Survival, Risk Assessment methods, Risk Assessment statistics & numerical data, Skin Neoplasms genetics, Skin Neoplasms immunology, Skin Neoplasms mortality, Biomarkers, Tumor analysis, Immune Checkpoint Inhibitors therapeutic use, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Aim: Summarize the literature assessing biomarkers in predicting efficacy of anti-PD-1 therapy for patients with high-risk unresectable or metastatic melanoma. Materials & methods: Relevant studies were identified via a systematic literature review. Results: About 334 unique biomarkers or biomarker combinations were identified from 121 citations. Neutrophil-to-lymphocyte ratio was the most frequently studied biomarker, followed by C-reactive protein. Fifty-nine biomarkers were significantly associated with overall survival (OS), 51 with progression-free survival (PFS) and 44 with response. Twenty biomarkers were associated with both OS and PFS; two were associated with OS, PFS and response (MHC-II and tumor mutational burden). Conclusion: Numerous biomarkers could potentially predict the efficacy of anti-PD-1-based therapy for melanoma patients. However, confirmatory studies are needed as well as determination of implications for clinical decision-making.
- Published
- 2021
- Full Text
- View/download PDF
33. Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro.
- Author
-
Hübner MP, Martin C, Specht S, Koschel M, Dubben B, Frohberger SJ, Ehrens A, Fendler M, Struever D, Mitre E, Vallarino-Lhermitte N, Gokool S, Lustigman S, Schneider M, Townson S, Hoerauf A, and Scandale I
- Subjects
- Animals, Anthelmintics therapeutic use, Disease Models, Animal, Elephantiasis, Filarial parasitology, Female, Filarioidea embryology, Gerbillinae parasitology, Mice, Mice, Inbred BALB C, Microfilariae drug effects, Onchocerca drug effects, Onchocerca volvulus drug effects, Onchocerciasis drug therapy, Benzimidazoles pharmacology, Elephantiasis, Filarial drug therapy, Filarioidea drug effects
- Abstract
A major impediment to eliminate lymphatic filariasis and onchocerciasis is the lack of effective short-course macrofilaricidal drugs or regimens that are proven to be safe for both infections. In this study we tested oxfendazole, an anthelmintic shown to be well tolerated in phase 1 clinical trials. In vitro, oxfendazole exhibited modest to marginal motility inhibition of adult worms of Onchocerca gutturosa, pre-adult worms of Onchocerca volvulus and Onchocerca lienalis microfilariae. In vivo, five days of oral treatments provided sterile cure with up to 100% macrofilaricidal efficacy in the murine Litomosoides sigmodontis model of filariasis. In addition, 10 days of oral treatments with oxfendazole inhibited filarial embryogenesis in patent L. sigmodontis-infected jirds and subsequently led to a protracted but complete clearance of microfilaremia. The macrofilaricidal effect observed in vivo was selective, as treatment with oxfendazole of microfilariae-injected naïve mice was ineffective. Based on pharmacokinetic analysis, the driver of efficacy is the maintenance of a minimal efficacious concentration of approximately 100 ng/ml (based on subcutaneous treatment at 25 mg/kg in mice). From animal models, the human efficacious dose is predicted to range from 1.5 to 4.1 mg/kg. Such a dose has already been proven to be safe in phase 1 clinical trials. Oxfendazole therefore has potential to be efficacious for treatment of human filariasis without causing adverse reactions due to drug-induced microfilariae killing., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
34. Whence river blindness? The domestication of mammals and host-parasite co-evolution in the nematode genus Onchocerca.
- Author
-
Lefoulon E, Giannelli A, Makepeace BL, Mutafchiev Y, Townson S, Uni S, Verocai GG, Otranto D, and Martin C
- Subjects
- Animals, Animals, Domestic genetics, Electron Transport Complex IV genetics, Electron Transport Complex IV metabolism, Gene Expression Regulation, Enzymologic, Humans, Animals, Domestic parasitology, Biological Coevolution, Mammals parasitology, Onchocerca genetics, Onchocerca physiology
- Abstract
The genus Onchocerca includes 34 described species and represents one of the largest genera of the filarial nematodes within the family Onchocercidae. Representative members of this genus are mainly parasites of ungulates, with some exceptions such as Onchocerca lupi and Onchocerca volvulus, infecting carnivores and/or humans. For a long time, the evolutionary relationships amongst onchocercids remained poorly studied, as the systematics of this genus was impaired by the high morphological variability of species included in the taxon. Although some molecular phylogenies were developed, these studies were mainly focused on bovine Onchocerca spp. and O. volvulus, including assessments of Wolbachia endosymbionts. In the present study, we analysed 13 Onchocerca spp. from a larger host spectrum using a panel of seven different genes. Analysis of the coxI marker supports its usefulness for the identification of species within the genus. The evolutionary history of the genus has been herein revised by multi-gene phylogenies, presenting three strongly supported clades of Onchocerca spp. Analyses of co-evolutionary scenarios between Onchocerca and their vertebrate hosts underline the effect of domestication on Onchocerca speciation. Our study indicates that a host switch event occurred between Bovidae, Canidae and humans. Cophylogenetic analyses between Onchocerca and the endosymbiotic bacterium Wolbachia indicate the strongest co-evolutionary pattern ever registered within the filarial nematodes. Finally, this dataset indicates that the clade composed by O. lupi, Onchocerca gutturosa, Onchocerca lienalis, Onchocerca ochengi and O. volvulus derived from recent speciation., (Copyright © 2017. Published by Elsevier Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
35. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.
- Author
-
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Alemán Resto Y, Alsibaee A, Alzualde A, Andrews KT, Avery SV, Avery VM, Ayong L, Baker M, Baker S, Ben Mamoun C, Bhatia S, Bickle Q, Bounaadja L, Bowling T, Bosch J, Boucher LE, Boyom FF, Brea J, Brennan M, Burton A, Caffrey CR, Camarda G, Carrasquilla M, Carter D, Belen Cassera M, Chih-Chien Cheng K, Chindaudomsate W, Chubb A, Colon BL, Colón-López DD, Corbett Y, Crowther GJ, Cowan N, D'Alessandro S, Le Dang N, Delves M, DeRisi JL, Du AY, Duffy S, Abd El-Salam El-Sayed S, Ferdig MT, Fernández Robledo JA, Fidock DA, Florent I, Fokou PV, Galstian A, Gamo FJ, Gokool S, Gold B, Golub T, Goldgof GM, Guha R, Guiguemde WA, Gural N, Guy RK, Hansen MA, Hanson KK, Hemphill A, Hooft van Huijsduijnen R, Horii T, Horrocks P, Hughes TB, Huston C, Igarashi I, Ingram-Sieber K, Itoe MA, Jadhav A, Naranuntarat Jensen A, Jensen LT, Jiang RH, Kaiser A, Keiser J, Ketas T, Kicka S, Kim S, Kirk K, Kumar VP, Kyle DE, Lafuente MJ, Landfear S, Lee N, Lee S, Lehane AM, Li F, Little D, Liu L, Llinás M, Loza MI, Lubar A, Lucantoni L, Lucet I, Maes L, Mancama D, Mansour NR, March S, McGowan S, Medina Vera I, Meister S, Mercer L, Mestres J, Mfopa AN, Misra RN, Moon S, Moore JP, Morais Rodrigues da Costa F, Müller J, Muriana A, Nakazawa Hewitt S, Nare B, Nathan C, Narraidoo N, Nawaratna S, Ojo KK, Ortiz D, Panic G, Papadatos G, Parapini S, Patra K, Pham N, Prats S, Plouffe DM, Poulsen SA, Pradhan A, Quevedo C, Quinn RJ, Rice CA, Abdo Rizk M, Ruecker A, St Onge R, Salgado Ferreira R, Samra J, Robinett NG, Schlecht U, Schmitt M, Silva Villela F, Silvestrini F, Sinden R, Smith DA, Soldati T, Spitzmüller A, Stamm SM, Sullivan DJ, Sullivan W, Suresh S, Suzuki BM, Suzuki Y, Swamidass SJ, Taramelli D, Tchokouaha LR, Theron A, Thomas D, Tonissen KF, Townson S, Tripathi AK, Trofimov V, Udenze KO, Ullah I, Vallieres C, Vigil E, Vinetz JM, Voong Vinh P, Vu H, Watanabe NA, Weatherby K, White PM, Wilks AF, Winzeler EA, Wojcik E, Wree M, Wu W, Yokoyama N, Zollo PH, Abla N, Blasco B, Burrows J, Laleu B, Leroy D, Spangenberg T, Wells T, and Willis PA
- Subjects
- Drug Evaluation, Preclinical, Humans, Small Molecule Libraries, Antimalarials therapeutic use, Datasets as Topic, Drug Discovery methods, Malaria drug therapy, Neglected Diseases drug therapy
- Abstract
A major cause of the paucity of new starting points for drug discovery is the lack of interaction between academia and industry. Much of the global resource in biology is present in universities, whereas the focus of medicinal chemistry is still largely within industry. Open source drug discovery, with sharing of information, is clearly a first step towards overcoming this gap. But the interface could especially be bridged through a scale-up of open sharing of physical compounds, which would accelerate the finding of new starting points for drug discovery. The Medicines for Malaria Venture Malaria Box is a collection of over 400 compounds representing families of structures identified in phenotypic screens of pharmaceutical and academic libraries against the Plasmodium falciparum malaria parasite. The set has now been distributed to almost 200 research groups globally in the last two years, with the only stipulation that information from the screens is deposited in the public domain. This paper reports for the first time on 236 screens that have been carried out against the Malaria Box and compares these results with 55 assays that were previously published, in a format that allows a meta-analysis of the combined dataset. The combined biochemical and cellular assays presented here suggest mechanisms of action for 135 (34%) of the compounds active in killing multiple life-cycle stages of the malaria parasite, including asexual blood, liver, gametocyte, gametes and insect ookinete stages. In addition, many compounds demonstrated activity against other pathogens, showing hits in assays with 16 protozoa, 7 helminths, 9 bacterial and mycobacterial species, the dengue fever mosquito vector, and the NCI60 human cancer cell line panel of 60 human tumor cell lines. Toxicological, pharmacokinetic and metabolic properties were collected on all the compounds, assisting in the selection of the most promising candidates for murine proof-of-concept experiments and medicinal chemistry programs. The data for all of these assays are presented and analyzed to show how outstanding leads for many indications can be selected. These results reveal the immense potential for translating the dispersed expertise in biological assays involving human pathogens into drug discovery starting points, by providing open access to new families of molecules, and emphasize how a small additional investment made to help acquire and distribute compounds, and sharing the data, can catalyze drug discovery for dozens of different indications. Another lesson is that when multiple screens from different groups are run on the same library, results can be integrated quickly to select the most valuable starting points for subsequent medicinal chemistry efforts.
- Published
- 2016
- Full Text
- View/download PDF
36. Characterization of the Ca2+-gated and voltage-dependent K+-channel Slo-1 of nematodes and its interaction with emodepside.
- Author
-
Kulke D, von Samson-Himmelstjerna G, Miltsch SM, Wolstenholme AJ, Jex AR, Gasser RB, Ballesteros C, Geary TG, Keiser J, Townson S, Harder A, and Krücken J
- Subjects
- Animals, Caenorhabditis elegans drug effects, Caenorhabditis elegans genetics, Caenorhabditis elegans Proteins drug effects, Caenorhabditis elegans Proteins genetics, Calcium metabolism, Large-Conductance Calcium-Activated Potassium Channels drug effects, Large-Conductance Calcium-Activated Potassium Channels genetics, Patch-Clamp Techniques, Phylogeny, Xenopus laevis, Anthelmintics pharmacology, Caenorhabditis elegans Proteins physiology, Depsipeptides pharmacology, Large-Conductance Calcium-Activated Potassium Channels physiology
- Abstract
The cyclooctadepsipeptide emodepside and its parent compound PF1022A are broad-spectrum nematicidal drugs which are able to eliminate nematodes resistant to other anthelmintics. The mode of action of cyclooctadepsipeptides is only partially understood, but involves the latrophilin Lat-1 receptor and the voltage- and calcium-activated potassium channel Slo-1. Genetic evidence suggests that emodepside exerts its anthelmintic activity predominantly through Slo-1. Indeed, slo-1 deficient Caenorhabditis elegans strains are completely emodepside resistant. However, direct effects of emodepside on Slo-1 have not been reported and these channels have only been characterized for C. elegans and related Strongylida. Molecular and bioinformatic analyses identified full-length Slo-1 cDNAs of Ascaris suum, Parascaris equorum, Toxocara canis, Dirofilaria immitis, Brugia malayi, Onchocerca gutturosa and Strongyloides ratti. Two paralogs were identified in the trichocephalids Trichuris muris, Trichuris suis and Trichinella spiralis. Several splice variants encoding truncated channels were identified in Trichuris spp. Slo-1 channels of trichocephalids form a monophyletic group, showing that duplication occurred after the divergence of Enoplea and Chromadorea. To explore the function of a representative protein, C. elegans Slo-1a was expressed in Xenopus laevis oocytes and studied in electrophysiological (voltage-clamp) experiments. Incubation of oocytes with 1-10 µM emodepside caused significantly increased currents over a wide range of step potentials in the absence of experimentally increased intracellular Ca2+, suggesting that emodepside directly opens C. elegans Slo-1a. Emodepside wash-out did not reverse the effect and the Slo-1 inhibitor verruculogen was only effective when applied before, but not after, emodepside. The identification of several splice variants and paralogs in some parasitic nematodes suggests that there are substantial differences in channel properties among species. Most importantly, this study showed for the first time that emodepside directly opens a Slo-1 channel, significantly improving the understanding of the mode of action of this drug class.
- Published
- 2014
- Full Text
- View/download PDF
37. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis.
- Author
-
Johnston KL, Ford L, Umareddy I, Townson S, Specht S, Pfarr K, Hoerauf A, Altmeyer R, and Taylor MJ
- Abstract
Lymphatic filariasis and onchocerciasis are debilitating diseases caused by parasitic filarial nematodes infecting around 150 million people throughout the tropics with more than 1.5 billion at risk. As with other neglected tropical diseases, classical drug-discovery and development is lacking and a 50 year programme of macrofilaricidal discovery failed to deliver a drug which can be used as a public health tool. Recently, antibiotic targeting of filarial Wolbachia, an essential bacterial symbiont, has provided a novel drug treatment for filariasis with macrofilaricidal activity, although the current gold-standard, doxycycline, is unsuitable for use in mass drug administration (MDA). The anti-Wolbachia (A·WOL) Consortium aims to identify novel anti-Wolbachia drugs, compounds or combinations that are suitable for use in MDA. Development of a Wolbachia cell-based assay has enabled the screening of the approved human drug-pharmacopoeia (∼2600 drugs) for a potential repurposing. This screening strategy has revealed that approved drugs from various classes show significant bacterial load reduction equal to or superior to the gold-standard doxycycline, with 69 orally available hits from different drug categories being identified. Based on our defined hit criteria, 15 compounds were then selectively screened in a Litomosoides sigmodontis mouse model, 4 of which were active. These came from the tetracycline, fluoroquinolone and rifamycin classes. This strategy of repurposing approved drugs is a promising development in the goal of finding a novel treatment against filariasis and could also be a strategy applicable for other neglected tropical diseases.
- Published
- 2014
- Full Text
- View/download PDF
38. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis.
- Author
-
Taylor MJ, Hoerauf A, Townson S, Slatko BE, and Ward SA
- Subjects
- Animals, Brugia malayi drug effects, Brugia malayi microbiology, Brugia malayi physiology, Child, Doxycycline pharmacology, Drug Discovery, Elephantiasis, Filarial parasitology, Female, Humans, Ivermectin pharmacology, Loiasis parasitology, Onchocerca volvulus drug effects, Onchocerca volvulus microbiology, Onchocerca volvulus physiology, Onchocerciasis parasitology, Pregnancy, Symbiosis drug effects, Wolbachia growth & development, Anti-Bacterial Agents pharmacology, Elephantiasis, Filarial drug therapy, Filaricides pharmacology, Loiasis drug therapy, Onchocerciasis drug therapy, Wolbachia drug effects
- Abstract
Anti-Wolbachia therapy delivers safe macrofilaricidal activity with superior therapeutic outcomes compared to all standard anti-filarial treatments, with the added benefit of substantial improvements in clinical pathology. These outcomes can be achieved, in principle, with existing registered drugs, e.g. doxycycline, that are affordable, available to endemic communities and have well known, albeit population-limiting, safety profiles. The key barriers to using doxycycline as an mass drug administration (MDA) strategy for widespread community-based control are the logistics of a relatively lengthy course of treatment (4-6 weeks) and contraindications in children under eight years and pregnancy. Therefore, the primary goal of the anti-Wolbachia (A·WOL) consortium is to find drugs and regimens that reduce the period of treatment from weeks to days (7 days or less), and to find drugs which would be safe in excluded target populations (pregnancy and children). A secondary goal is to refine regimens of existing antibiotics suitable for a more restricted use, prior to the availability of a regimen that is compatible with MDA usage. For example, for use in the event of the emergence of drug-resistance, in individuals with high loiasis co-infection and at risk of severe adverse events (SAE) to ivermectin, or in post-MDA 'endgame scenarios', where test and treat strategies become more cost effective and deliverable.
- Published
- 2014
- Full Text
- View/download PDF
39. Integrated dataset of screening hits against multiple neglected disease pathogens.
- Author
-
Nwaka S, Besson D, Ramirez B, Maes L, Matheeussen A, Bickle Q, Mansour NR, Yousif F, Townson S, Gokool S, Cho-Ngwa F, Samje M, Misra-Bhattacharya S, Murthy PK, Fakorede F, Paris JM, Yeates C, Ridley R, Van Voorhis WC, and Geary T
- Subjects
- Drug Discovery trends, Humans, Antiparasitic Agents isolation & purification, Drug Evaluation, Preclinical methods, Neglected Diseases drug therapy, Parasitic Diseases drug therapy
- Abstract
New chemical entities are desperately needed that overcome the limitations of existing drugs for neglected diseases. Screening a diverse library of 10,000 drug-like compounds against 7 neglected disease pathogens resulted in an integrated dataset of 744 hits. We discuss the prioritization of these hits for each pathogen and the strong correlation observed between compounds active against more than two pathogens and mammalian cell toxicity. Our work suggests that the efficiency of early drug discovery for neglected diseases can be enhanced through a collaborative, multi-pathogen approach.
- Published
- 2011
- Full Text
- View/download PDF
40. Challenges in drug discovery for novel antifilarials.
- Author
-
Townson S, Ramirez B, Fakorede F, Mouries MA, and Nwaka S
- Abstract
Control programmes are at present focused on the elimination of onchocerciasis and lymphatic filariasis as public health problems in countries where they are endemic. The availability of effective drugs used in combination (diethylcarbamazine, albendazole and ivermectin) has paved the way for the implementation of Mass Drug Administration (MDA) campaigns. Considerable progress in the implementation of MDA programmes had led to significant reductions in transmission and morbidity. However, new drugs are needed to overcome the threat of resistance to existing microfilaricides as well as to identify new macrofilaricides. This paper discusses the existing screening tools available for antifilarial drug discovery and efforts towards optimising their use through the Helminth Drug Initiative.
- Published
- 2007
- Full Text
- View/download PDF
41. Onchocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro.
- Author
-
Townson S, Tagboto S, McGarry HF, Egerton GL, and Taylor MJ
- Abstract
Background: The filarial parasites of major importance in humans contain the symbiotic bacterium Wolbachia and recent studies have shown that targeting of these bacteria with antibiotics results in a reduction in worm viability, development, embryogenesis, and survival. Doxycycline has been effective in human trials, but there is a need to develop drugs that can be given for shorter periods and to pregnant women and children. The World Health Organisation-approved assay to screen for anti-filarial activity in vitro uses male Onchocerca gutturosa, with effects being determined by worm motility and viability as measured by reduction of MTT to MTT formazan. Here we have used this system to screen antibiotics for anti-filarial activity. In addition we have determined the contribution of Wolbachia depletion to the MTT reduction assay., Methods: Adult male O. gutturosa were cultured on a monkey kidney cell (LLCMK 2) feeder layer in 24-well plates with antibiotics and antibiotic combinations (6 to 10 worms per group). The macrofilaricide CGP 6140 (Amocarzine) was used as a positive control. Worm viability was assessed by two methods, (i) motility levels and (ii) MTT/formazan colorimetry. Worm motility was scored on a scale of 0 (immotile) to 10 (maximum) every 5 days up to 40 days. On day 40 worm viability was evaluated by MTT/formazan colorimetry, and results were expressed as a mean percentage reduction compared with untreated control values at day 40. To determine the contribution of Wolbachia to the MTT assay, the MTT formazan formation of an insect cell-line (C6/36) with or without insect Wolbachia infection and treated or untreated with tetracycline was compared., Results: Antibiotics with known anti-Wolbachia activity were efficacious in this system. Rifampicin (5 x 10(-5) M) was the most effective anti-mycobacterial agent; clofazimine (1.25 x 10(-5) M and 3.13 x 10(-6) M) produced a gradual reduction in motility and by 40 days had reduced worm viability. The other anti-mycobacterial drugs tested had limited or no activity. Doxycycline (5 x 10(-5) M) was filaricidal, but minocycline was more effective and at a lower concentration (5 x 10(-5) M and 1.25 x 10(-5) M). Inactive compounds included erythromycin, oxytetracycline, trimethoprim and sulphamethoxazole. The MTT assay on the insect cell-line showed that Wolbachia made a significant contribution to the metabolic activity within the cells, which could be reduced when they were exposed to tetracycline., Conclusion: The O. gutturosa adult male screen for anti-filarial drug activity is also valid for the screening of antibiotics for anti-Wolbachia activity. In agreement with previous findings, rifampicin and doxycycline were effective; however, the most active antibiotic was minocycline. Wolbachia contributed to the formation of MTT formazan in the MTT assay of viability and is therefore not exclusively a measure of worm viability and indicates that Wolbachia contributes directly to the metabolic activity of the nematode.
- Published
- 2006
- Full Text
- View/download PDF
42. Potential transition state phosphoramidate inhibitors of beta-tubulin as antifilarial agents.
- Author
-
Anderson RJ, Bendell DJ, Hooper M, Cairns D, Mackay SP, Hiremath SP, Jivanagi AS, Badami S, Biradar JS, and Townson S
- Subjects
- Animals, Benzimidazoles chemical synthesis, Benzimidazoles pharmacology, Brugia pahangi drug effects, Carbon Tetrachloride chemistry, Filaricides chemical synthesis, Filaricides pharmacology, Temperature, Amides pharmacology, Benzimidazoles chemistry, Filaricides chemistry, Phosphoric Acids pharmacology, Tubulin Modulators
- Abstract
Transition state phosphoramidate inhibitors of beta-tubulin were designed as potential antifilarial agents. The reaction of 2-aminobenzimidazole with diisopropyl phosphite and carbon tetrachloride at a low temperature gave the unexpected 1-diisopropoxyphosphoryl-2-aminobenzimidazole, which on heating gave the novel benzimidazole derivative, 2-(diisopropoxyphosphoryl)aminobenzimidazole. Both products were fully characterized and the synthetic procedure to both compounds was optimized. The procedure was used to prepare the related 5-benzoyl-2-(diisopropoxyphosphoryl)aminobenzimidazole and 5-benzoyl-2-(diethoxyphosphoryl)aminobenzimidazole (1d). In a preliminary trial against Brugia pahangi compound 1d was found to have no antifilarial activity. This lack of activity may be attributed to its extreme insolubility and thus low bioavailability. The synthesis of analogous, more soluble, phosphorothioate-substituted benzimidazoles using the same methods may yield compounds with greater antifilarial activity.
- Published
- 2001
- Full Text
- View/download PDF
43. Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi.
- Author
-
Townson S, Hutton D, Siemienska J, Hollick L, Scanlon T, Tagboto SK, and Taylor MJ
- Subjects
- Animals, Brugia pahangi ultrastructure, Cattle, Chloramphenicol therapeutic use, Female, Gerbillinae, Male, Mice, Mice, Inbred CBA, Microscopy, Electron, Oxytetracycline therapeutic use, Rifampin therapeutic use, Treatment Outcome, Wolbachia ultrastructure, Anti-Bacterial Agents therapeutic use, Brugia pahangi drug effects, Filariasis drug therapy, Onchocerciasis drug therapy, Wolbachia drug effects
- Abstract
The activity against filarial parasites of the antibiotics rifampicin, oxytetracycline and chloramphenicol was examined. In addition, transmission electron microscopy was used to study the effects of rifampicin and oxytetracycline on filarial tissues and on the endosymbiont bacterium, Wolbachia. When tested in vitro at a concentration of 50.0 microM, each of the three antibiotics significantly reduced the motility levels of male Onchocerca gutturosa. Rifampicin, however, was the most active, virtually immobilizing the parasite by the end of the 40-day trial and producing an 84% reduction in viability (as measured by formazan-based colorimetry). In tests against O. lienalis microfilariae (mff) in CBA mice, the numbers of mff recovered after treatment with oxytetracycline at 100, 25 or 6.5 mg/kg daily, for 15 days, were 56% (P < or = 0.03), 38% (P> 0.05) and 45% (P = 0.05) less than that recovered from the untreated controls, respectively. In another trial in mice, rifampicin (100 mg/kg daily for 15 days) was found to be the most active (causing a 74% reduction in the number of mff recovered--approximately equal to that achieved with the positive control of a single dose of ivermectin at 2 microg/kg), with chloramphenicol also showing significant activity (39% reduction). In further, in-vivo trials, at three dose levels (100, 25 or 6.25 mg/kg daily, for 15 days), all three antibiotics were tested against adult Brugia pahangi in the peritoneal cavities of jirds. None of the antibiotics produced a significant reduction in the numbers of live worms recovered, although a marginal effect was observed in eight of the nine antibiotic-treated groups. A further extended trial with rifampicin and oxytetracycline resulted in 43% and 38% reductions in worm recoveries, respectively (not statistically significant but consistent with a marginal effect); some of these worms appeared less motile and qualitatively in poor condition compared with those recovered from untreated jirds. Ultrastructural studies of these treated worms revealed that virtually all of the endosymbiont bacteria had been cleared from the parasite tissues. The tissues of the adult worms appeared to be largely intact but with a granulomatous response of host cells adhering to some specimens. However, developing uterine forms appeared to be abnormal and extensively damaged, showing an abrogation of embryogenesis. In contrast, worms recovered from control animals contained large numbers of Wolbachia, had no adherent host cells, and showed normal ultrastructure; the female worms exhibited a full range of intra-uterine developing stages from eggs to stretched mff. It is likely that the activity of these antibiotics against the endosymbiont Wolbachia causes the observed antifilarial activity, although some direct effect of each drug on filarial viability cannot be ruled out.
- Published
- 2000
- Full Text
- View/download PDF
44. HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
- Author
-
Townson SM, Sullivan T, Zhang Q, Clark GM, Osborne CK, Lee AV, and Oesterreich S
- Subjects
- 3T3 Cells metabolism, Animals, Breast Neoplasms metabolism, CHO Cells metabolism, Cell Division physiology, Cell Nucleus physiology, Cricetinae, DNA-Binding Proteins biosynthesis, DNA-Binding Proteins genetics, Gene Expression, Green Fluorescent Proteins, Humans, Luminescent Proteins biosynthesis, Luminescent Proteins genetics, Mice, Nuclear Proteins biosynthesis, Nuclear Proteins genetics, Recombinant Fusion Proteins biosynthesis, Recombinant Fusion Proteins genetics, Transfection, Tumor Cells, Cultured, Aneuploidy, Breast Neoplasms genetics, Breast Neoplasms pathology, DNA-Binding Proteins physiology, Matrix Attachment Region Binding Proteins, Nuclear Matrix-Associated Proteins, Nuclear Proteins physiology, Receptors, Estrogen
- Abstract
HET/SAF-B was originally cloned as a nuclear matrix protein that bound to matrix attachment regions and as a transcriptional repressor of the small heat shock protein hsp27. In addition, we have found recently that HET/SAF-B is also a corepressor of estrogen receptor activity. Estrogen receptor has a very well-described role in breast cancer, and aberrant expression of nuclear matrix and heat shock proteins has also been implicated in breast tumorigenesis. Therefore, we asked whether HET/SAF-B itself could be important in breast cancer. Toward this goal we examined its expression in breast cancer cell lines and asked whether HET/SAF-B can affect breast cancer cell proliferation. Finally, we studied HET/SAF-B expression in clinical breast cancer samples. HET/SAF-B protein and mRNA were detected at varying levels in all of the eight breast cancer cell lines examined. Using a number of different approaches to modulate the level of HET/SAF-B protein in the cell, we found that HET/SAF-B levels are inversely correlated with cell proliferation. In addition,transfection of HET/SAF-B fused to the green fluorescent protein led to the formation of multinucleated cells not observed in cells transfected with green fluorescent protein alone, suggesting that this effect is a direct result of HET/SAF-B overexpression. Western blot analysis of HET/SAF-B in 61 human breast tumors revealed widely varying levels of HET/SAF-B expression, with some tumors (16%) lacking any detectable HET/SAF-B. Statistical analysis showed that high HET/SAF-B expression in these tumors was associated with low S-phase fraction and with aneuploidy, consistent with our results from transfection experiments in tissue culture cells. We conclude that HET/SAF-B plays an important role in breast cancer, and we discuss possible mechanisms of the involvement of HET/SAF-B in cell proliferation and division.
- Published
- 2000
45. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia.
- Author
-
Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, Mould A, Cahill MM, Tonks ID, Grimmond SM, Townson S, Wells C, Little M, Cummings MC, Hayward NK, and Kay GF
- Subjects
- Aging, Animals, Animals, Newborn, Coronary Vessel Anomalies metabolism, Coronary Vessels metabolism, Endothelial Growth Factors genetics, Endothelial Growth Factors metabolism, Female, Heart physiology, Heart Defects, Congenital physiopathology, Immunohistochemistry, Male, Mice, Mice, Knockout, Myocardial Ischemia physiopathology, Myocardium metabolism, Vascular Endothelial Growth Factor B, Coronary Vessel Anomalies genetics, Endothelial Growth Factors physiology, Heart growth & development, Heart Defects, Congenital genetics, Myocardial Ischemia genetics
- Abstract
Vascular endothelial growth factor-B (VEGF-B) is closely related to VEGF-A, an effector of blood vessel growth during development and disease and a strong candidate for angiogenic therapies. To further study the in vivo function of VEGF-B, we have generated Vegfb knockout mice (Vegfb(-/-)). Unlike Vegfa knockout mice, which die during embryogenesis, Vegfb(-/-) mice are healthy and fertile. Despite appearing overtly normal, Vegfb(-/-) hearts are reduced in size and display vascular dysfunction after coronary occlusion and impaired recovery from experimentally induced myocardial ischemia. These findings reveal a role for VEGF-B in the development or function of coronary vasculature and suggest potential clinical use in therapeutic angiogenesis.
- Published
- 2000
- Full Text
- View/download PDF
46. Honeybee blue- and ultraviolet-sensitive opsins: cloning, heterologous expression in Drosophila, and physiological characterization.
- Author
-
Townson SM, Chang BS, Salcedo E, Chadwell LV, Pierce NE, and Britt SG
- Subjects
- Animals, Base Sequence, Cloning, Molecular, Color, Gene Expression, Genes, Insect, Molecular Sequence Data, Sequence Homology, Amino Acid, Ultraviolet Rays, Bees genetics, Drosophila genetics, Rod Opsins genetics
- Abstract
The honeybee (Apis mellifera) visual system contains three classes of retinal photoreceptor cells that are maximally sensitive to light at 440 nm (blue), 350 nm (ultraviolet), and 540 nm (green). We performed a PCR-based screen to identify the genes encoding the Apis blue- and ultraviolet (UV)-sensitive opsins. We obtained cDNAs that encode proteins having a high degree of sequence and structural similarity to other invertebrate and vertebrate visual pigments. The Apis blue opsin cDNA encodes a protein of 377 amino acids that is most closely related to other invertebrate visual pigments that are thought to be blue-sensitive. The UV opsin cDNA encodes a protein of 371 amino acids that is most closely related to the UV-sensitive Drosophila Rh3 and Rh4 opsins. To test whether these novel Apis opsin genes encode functional visual pigments and to determine their spectral properties, we expressed them in the R1-6 photoreceptor cells of blind ninaE mutant Drosophila, which lack the major opsin of the fly compound eye. We found that the expression of either the Apis blue- or UV-sensitive opsin in transgenic flies rescued the visual defect of ninaE mutants, indicating that both genes encode functional visual pigments. Spectral sensitivity measurements of these flies demonstrated that the blue and UV visual pigments are maximally sensitive to light at 439 and 353 nm, respectively. These maxima are in excellent agreement with those determined previously by single-cell recordings from Apis photoreceptor cells and provide definitive evidence that the genes described here encode visual pigments having blue and UV sensitivity.
- Published
- 1998
47. Identification of a novel Drosophila opsin reveals specific patterning of the R7 and R8 photoreceptor cells.
- Author
-
Chou WH, Hall KJ, Wilson DB, Wideman CL, Townson SM, Chadwell LV, and Britt SG
- Subjects
- Animals, Base Sequence, Cloning, Molecular, Drosophila genetics, Genes, Molecular Sequence Data, Mutation, Photoreceptor Cells, Invertebrate cytology, Photoreceptor Cells, Invertebrate metabolism, Polymerase Chain Reaction, Rod Opsins genetics, Tissue Distribution, Drosophila metabolism, Rod Opsins metabolism
- Abstract
The function of the compound eye is dependent upon a developmental program that specifies different cell fates and directs the expression of spectrally distinct opsins in different photoreceptor cells. Rh5 is a novel Drosophila opsin gene that encodes a biologically active visual pigment that is expressed in a subset of R8 photoreceptor cells. Rh5 expression in the R8 cell of an individual ommatidium is strictly coordinated with the expression of Rh3, in the overlying R7 cell. In sevenless mutant files, which lack R7 photoreceptor cells, the expression of the Rh5 protein in R8 cells is disrupted, providing evidence for a specific developmental signal between the R7 and R8 cells that is responsible for the paired expression of opsin genes.
- Published
- 1996
- Full Text
- View/download PDF
48. Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo.
- Author
-
Tagboto SK and Townson S
- Subjects
- Animals, Anti-Bacterial Agents, Dose-Response Relationship, Drug, Macrolides therapeutic use, Mice, Mice, Inbred CBA, Microfilariae drug effects, Onchocerciasis parasitology, Time Factors, Anthelmintics therapeutic use, Ivermectin therapeutic use, Onchocerca volvulus, Onchocerciasis drug therapy
- Abstract
The activity of the veterinary drug moxidectin against Onchocerca volvulus and On. lienalis microfilariae (mf), both in vitro and in experimentally infected CBA/Ca mice, was compared with that of ivermectin. The in-vitro results demonstrated that both compounds (at a concentration of 10(-7) M) significantly reduced the mf motility index (MI) throughout the 7-day culture period and that this reduction was similar for the two compounds. Mice were treated with moxidectin and ivermectin by subcutaneous injection (sc) or orally (po); the two routes were equally efficacious. When mice infected with On. lienalis were treated with one of the drugs at 3.2, 1.6, 0.8, 0.4 or 0.2 micrograms/kg.day on days 3-7 post-infection, with necropsy on day 18, moxidectin cleared more mf than ivermectin at all of the doses examined. In mice treated with a single dose (on day 3 post-infection), 150 or 15 micrograms/kg moxidectin completely cleared the mf whereas 1.5 micrograms/kg produced a 90%-96% reduction in mf recoveries. Following ivermectin treatment at the same doses, mf were virtually cleared at 150 micrograms/kg, with a 98% reduction at 15 micrograms/kg but no significant effect at 1.5 micrograms/kg. When mice with On. volvulus infections were treated with a single dose of moxidectin at 15 or 1.5 micrograms/kg, there were reductions in mf recoveries of 96% and 23%, respectively, compared with only a 48% reduction with 15 micrograms ivermectin/kg and a 2% increase with 1.5 micrograms ivermectin/kg. In order to examine the persistence and activity of each drug, mice were treated with a single dose of 150 micrograms/kg up to 28 days before infection. Moxidectin was found to be more efficacious (with subsequent 99.9% reduction in mf when given 28 days pre-infection and a 100% reduction when give 16 or 4 days before or 3 days after infection) than ivermectin (giving reductions of 57.1%, 66.7%, 100% and 100%, respectively). The further evaluation of moxidectin and its potential usefulness for the treatment of human onchocerciasis are discussed.
- Published
- 1996
- Full Text
- View/download PDF
49. Characterization of the murine VEGF-related factor gene.
- Author
-
Townson S, Lagercrantz J, Grimmond S, Silins G, Nordenskjöld M, Weber G, and Hayward N
- Subjects
- Amino Acid Sequence, Animals, Base Sequence, Carrier Proteins biosynthesis, Carrier Proteins chemistry, Cloning, Molecular, DNA Primers, DNA, Complementary, Exons, Gene Library, Humans, Introns, Liver metabolism, Lung metabolism, Mice, Molecular Sequence Data, Muscle, Skeletal metabolism, Myocardium metabolism, Organ Specificity, RNA Splicing, Sequence Homology, Amino Acid, Transcription, Genetic, Vascular Endothelial Growth Factor B, Brain metabolism, Carrier Proteins genetics
- Abstract
We describe here the molecular cloning and characterization of the murine homolog of the human vascular endothelial growth factor-related factor (VRF) gene. cDNAs for two alternatively spliced forms of the murine vrf gene have been isolated, the putative translation products of which differ at their carboxyl termini due to a shift in reading frame caused by insertion, or lack thereof, of exon 6, in a similar fashion to human VRF (hVRF). The message lacking exon 6 encodes a protein (mvrf167) with 86% identity and 92% conservation of amino acid residues with hVRF. The protein coding region of the gene spans approximately 5kb of genomic DNA and is composed of 8 exons ranging in size from 36 to 398bp. The genomic structure of murine vrf is highly conserved with the human homolog in relation to position of splice junctions and the presence of contiguous exons 6 and 7. A short polymorphic AC repeat is present in the 3' untranslated region of murine vrf. A major band of approximately 1.3kb was expressed in all adult mouse tissues examined.
- Published
- 1996
- Full Text
- View/download PDF
50. In vitro cultivation and development of Onchocerca volvulus and Onchocerca lienalis microfilariae.
- Author
-
Townson S and Tagboto SK
- Subjects
- Animals, Ecdysterone pharmacology, Female, Glutathione pharmacology, Humans, Onchocerca growth & development, Simuliidae parasitology, Onchocerca volvulus growth & development
- Abstract
Onchocerca volvulus and O. lienalis skin-derived microfilariae (mf) were cultured in vitro; parasite viability was assessed at intervals by measuring their ability to develop in Simulium ornatum. In the presence of monkey kidney feeder cells, both species retained full viability when cultured for up to 5 hr before intrathoracic injection into Simulium. In the absence of feeder cells and in contrast to O. lienalis, O. volvulus mf rapidly lost their viability. In further trials (including feeder cells), O. volvulus mf retained full viability for 14 days, while O. lienalis mf retained full viability for a least 19 days but with a proportion able to develop to third-stage larvae (L3) after 70 days in culture. In experiments using this system to culture O. volvulus mf (ex utero) derived from adult female worms but with the addition of reduced glutathione and/or 20-hydroxyecdysone, parasites were consistently more active over a 70-day period than those cultured without these additives. None of the mf cultured without additives were able to develop to L3 in Simulium when tested for up to 51 days in culture, while a proportion of mf incubated with reduced glutathione and/or 20-hydroxyecdysone produced small but significant numbers of L3 after 28, 43, and 51 days, representing the first time that uterine mf have been cultured to a form infective for the vector.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.